CN102614502A - Application of ulinastatin to preparing anti-HIV (Human Immunodeficiency Virus)-1 virus medicament - Google Patents
Application of ulinastatin to preparing anti-HIV (Human Immunodeficiency Virus)-1 virus medicament Download PDFInfo
- Publication number
- CN102614502A CN102614502A CN2012101231589A CN201210123158A CN102614502A CN 102614502 A CN102614502 A CN 102614502A CN 2012101231589 A CN2012101231589 A CN 2012101231589A CN 201210123158 A CN201210123158 A CN 201210123158A CN 102614502 A CN102614502 A CN 102614502A
- Authority
- CN
- China
- Prior art keywords
- hiv
- ulinastatin
- virus
- medicine
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title description 30
- 229950008558 ulinastatin Drugs 0.000 title description 25
- ODVKSTFPQDVPJZ-UHFFFAOYSA-N urinastatin Chemical compound C1C=CCCC11COC(C=2OC=CC=2)OC1 ODVKSTFPQDVPJZ-UHFFFAOYSA-N 0.000 title description 25
- 108010088854 urinastatin Proteins 0.000 title description 25
- 241000700605 Viruses Species 0.000 title description 22
- 241000725303 Human immunodeficiency virus Species 0.000 title description 18
- 230000036436 anti-hiv Effects 0.000 title description 2
- 210000004027 cell Anatomy 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 13
- 238000011282 treatment Methods 0.000 description 12
- 208000030507 AIDS Diseases 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 230000001629 suppression Effects 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 7
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 7
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 229940090044 injection Drugs 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 5
- 229960001852 saquinavir Drugs 0.000 description 5
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 4
- 230000007541 cellular toxicity Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 229960000311 ritonavir Drugs 0.000 description 4
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229960002555 zidovudine Drugs 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 229940122440 HIV protease inhibitor Drugs 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000004030 hiv protease inhibitor Substances 0.000 description 3
- 229960001936 indinavir Drugs 0.000 description 3
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 230000000798 anti-retroviral effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229940023080 viracept Drugs 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 108091005502 Aspartic proteases Proteins 0.000 description 1
- 102000035101 Aspartic proteases Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 1
- 206010048474 Fat redistribution Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 description 1
- 108010016183 Human immunodeficiency virus 1 p16 protease Proteins 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- BPYKTIZUTYGOLE-UHFFFAOYSA-N billirubin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(C=C3C(=C(C=C)C(=O)N3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-UHFFFAOYSA-N 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229960000884 nelfinavir Drugs 0.000 description 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses application of ulinastatin to preparing an anti-HIV (Human Immunodeficiency Virus)-1 virus medicament, wherein the concentration of the ulinastatin is 200-400 mug/ml. The medicament can be immediately used at a window phase after HIV infection, and can also be used at different stages after occurrence of AIDS (Acquired Immune Deficiency Syndrome). According to the medicament, the concentration of the ulinastatin is 400 mug/ml, the suppression rate of 100 percent for the HIV-1 virus can be achieved, and no obvious cytotoxicity effect exists in cytotoxicity test.
Description
Technical field
The present invention relates to the application of ulinastatin as preparation anti-HIV-1 virus drugs.
Background technology
AIDS has just spread in the whole world since 1970 with surprising rapidity, obtains huge progress aspect the AIDS preventing and treating in recent years, but still lacks the active drug that radical cure HIV infects.The therapeutic goal of present stage is: to greatest extent with persistent reduction virus load; Obtain immunity function restructuring and keep immunologic function; Improve the quality of living; Reduce the relevant M & M of HIV.Therapeutic Method comprises general treatment, antiviral therapy, recovery and improves the treatment of immunologic function and the treatment of opportunistic infection and malignant tumor.Wherein antiviral is the key of treatment.Appearance along with the hiv protease inhibitor; Efficient anti-retroviral conjoint therapy (highly active anti-retroviral therapy has just appearred; HAART) application; Improved the curative effect of anti-HIV greatly, significantly improved AIDS patient's quality of life and prognosis, the treatment of AIDS is a a progressive step.
Current main antiviral drugs: granted come into the market have 16 kinds, mainly divide three major types: ucleosides reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitor (PI).
Wherein protease inhibitor (protease inhibitor, PI): HIV-1 protease is a symmetric dimer, under the catalysis of this enzyme, HIV has two hatching egg Rhizoma Cynanchi Stauntonii bodies to be cracked into maturation protein, so this enzyme is extremely important to duplicating of virus.Protease inhibitor can through the CKIs enzyme promptly block HIV duplicate with maturation process in necessary protein synthesis, thereby suppress duplicating of HIV.This type of preparation comprises:
A. Saquinavir (saquinavir): the hiv protease inhibitor of efficient high selectivity.These article act on the later stage of HIV breeding, combine with the activation point of hiv protease, make it to lose the function of combination and hydrolytic cleavage polypeptide.These article suppress hiv protease and other anti HIV-1 virus medicine such as azidothymidine AZT, and the effect target enzyme system that suppresses hiv reverse transcriptase is different, and no crossing drug resistant virus produces.600mg, 2 times/d or 3 times/d.Side effect can have symptoms of digestive tract such as nausea,vomiting,diarrhea, also visible headache, transaminase's rising etc.
B. indinavir (indinavir): (hiv protease inhibitor and other antiretroviral drugs are united use.800mg, 3 times/d.That side effect has is nauseating, vomiting, headache, weak, dizzy, erythra etc., and can cause unconjugated bilirubin rising, thrombocytopenia, renal calculus, blood sugar increasing and fat redistribution etc.
C. viracept see nelfinaivr (nelfinavir): 750mg, 3 times/d.Side effect has diarrhoea, hyperglycemia etc.
D. oral effective inhibitor of ritonavir (ritonavir): HIV-1 and HIV-2 aspartic protease; Block this enzymatic and make the required polyprotein of ripe HIV granule in the generation morphology; Make the HIV granule thereby remain on immature state; Thereby slow down HIV spreading in cell, to prevent the generation that a new round infects and to postpone advancing of disease.These article are generally all effective with zidovudine and the drug-fast HIV strain of Saquinavir to the zidovudine sensitivity.300～600mg, 2 times/d.Side effect has nausea,vomiting,diarrhea, weak, paraesthesia, hepatic disfunction, triglyceride rising, uric acid increase, blood sugar increasing etc.
Above-mentioned three types of medicine majorities all have untoward reaction, and are single with very difficult effective duplicating of virus of suppressing, and are prone to the generation drug resistance.Therefore, stress drug combination.The scheme of drug combination is a lot, at present manyly adds two kinds of NRTI preparations with a kind of protease inhibitor, or two kinds of albumen enzyme inhibitors add one or two kind of NRTI preparation, and common scheme for combining has: Saquinavir ZDV 3TC; Or viracept see nelfinaivr D4T ddi; Or indinavir ZDV ddi; Or ritonavir ZDV ddc; Or Saquinavir ritonavir D4T 3TC.Use these scheme for combining treatments, can suppress a plurality of links of HIV reproduction process simultaneously, can efficiently suppress HIV and duplicate, reduce drug resistance to greatest extent, improve patients ' life quality and survival rate, significantly reduce the danger of mother and baby's vertical transmission etc.
HAART scheme for combining on opportunity about antiviral therapy is used the curative effect that is obtained, and arouses the confidence that people defeat AIDS again.Many doctors were thought getting over early treatment, effect is good more.But prolongation along with the time of application; Can suppress virus load in the blood to the level that does not detect although it is found that therapeutic alliance; But remove the virus of concealing in lymphocyte, macrophage and the nervous tissue and be not easy, treat decades possibly even take medicine all the life.Yet; Period in a medicine, except digestive tract reaction and bone marrow depression etc. the common adverse effect, these drug-induced other serious toxic and side effects; Patient's compliance, compliance are poor; The Drug resistance of HIV is increasing in addition, and the propagation of Drug resistance strain is more and more serious or the like, forces the doctor to consider treatment opportunity carefully.
Advocate at present: 1. be developed to AIDS person,, all should have treated regardless of the value height of CD4 and virus load; 2. asymptomatic person, < 200 * 106/L should treat though virus load can not surveyed also CD4; 3. cd4 cell>200 * 106/L, but < 350 * 106/L, virus load are not high, and the patient is asymptomatic, and the treatment of this moment still has arguement; 4. asymptomatic person's CD4>350 * 106/L, virus load>55000 copy numbers, advocate treatment at present mostly; 5. asymptomatic person's CD4>350 * 106/L, < 55000 copy numbers advocate to continue monitoring CD4 amount to virus load mostly at present; 6. be interrupted treatment.
Summary of the invention
Goal of the invention: the objective of the invention is to deficiency to prior art; A kind of morbidity that both can the window phase after infected by HIV prevents AIDS is provided; Can therapeutical effect be arranged to the patient who suffers from AIDS again, prevent recurrence, and not have the medicine of the anti-HIV-1 virus of obvious toxic and side effects.
Technical scheme: ulinastatin of the present invention is as the application of preparation anti-HIV-1 virus drugs, and the concentration of ulinastatin is 200～400 μ g/ml.
Preferably, the concentration of said ulinastatin is 400 μ g/ml, under this concentration, can reach 100% suppression ratio to HIV-1 virus.
Preferably, the concentration of said ulinastatin is 200 μ g/ml, under this concentration, can reach 99% suppression ratio to HIV-1 virus, and simultaneously, the toxic action of pair cell is littler, and Financial cost is lower.
Also comprise pharmaceutically acceptable auxiliaries in the said medicine.
Said medicine can be lyophilized injectable powder, and said pharmaceutically acceptable auxiliaries is any one or a few in mannitol, lactose, gelatin hydrolysate, sodium chloride or the glucose sugar.
Said medicine also can be injection, and said pharmaceutically acceptable auxiliaries is any one or a few in water for injection, mannitol, sodium chloride or the glucose.
Beneficial effect: 1, medicine of the present invention can use by the window phase after infected by HIV immediately, also can be used for the different phase that AIDS has taken place, and to compare toxic and side effects little with the medicine that has gone on the market; 2, medicine of the present invention when the concentration of ulinastatin is 400 μ g/ml, can reach 100% suppression ratio to HIV-1 virus, and in cytotoxicity test, not have the significant cytotoxicity effect; 3, for many years, in the clinical observation of using active constituents of medicine ulinastatin treatment acute pancreatitis of the present invention, not finding obvious toxic and side effects, is comparatively safe therefore.
The specific embodiment
Be elaborated in the face of technical scheme of the present invention down, but protection scope of the present invention is not limited to said embodiment.
Embodiment:Ulinastatin of the present invention is as the application of preparation anti-HIV-1 virus drugs, and the concentration of ulinastatin is 200～400 μ g/ml, and concentration can reach 100% suppression ratio when being 400 μ g/ml.
Utilize the anti-HIV-1 virus drugs of ulinastatin preparation, can use immediately by the window phase after infected by HIV, also can be used for the different phase that AIDS has taken place.The window phase dosage is ulinastatin 100,000 U, with 5% glucose injection 500ml dissolving 1-2 time/day, intravenous drip.When get into AIDS sick period then with various RTI Combined application.Medicine is usually with the intravenous route administration, and main dosage form is lyophilized injection or injection liquor.
When medicine was lyophilized injectable powder, pharmaceutically acceptable auxiliaries was any one or a few in mannitol, lactose, gelatin hydrolysate, sodium chloride or the glucose sugar, can be dissolved in use in go out water bacterium or various other injection sterile medium.
When medicine was injection, pharmaceutically acceptable auxiliaries was any one or a few in water for injection, mannitol, sodium chloride or the glucose.
The pharmacodynamic study test of AIDS virus resisting of the present invention is provided below:
1, material and medicine
1.1 medicine: after the ulinastatin water fully dissolves, after the bag filter dialysis, cultivate base with 1640 and be diluted to variable concentrations (the ulinastatin medicine is produced by the Dalian northern biological factory);
1.2 reagent: the P24 test kit is available from U.S. Organon Teknika company, and MTT (Thiazoll blue) is available from Sigma company;
1.3 cell: MT4 cell line is adopted to cultivate and is obtained, and culture medium is that RPMI-1640 adds 10% hyclone, 1% glutamine, 1% mycillin;
1.4 virus: the German strain of HIV-1 virus, Virology Inst., China Academy of Preventive Medicine Sciences preserves goes down to posterity.
2, experimental technique
2.1 inhibition test to the HIV-1 actute infection
Be diluted to 10,000 TCID 50/ml after HIV-1 melted, get the 5000000 MT4 cells (1800 rev/mins centrifugal 5 minutes) that viral liquid after the 1ml dilution adds centrifugal back and abandons supernatant, put in 37 ℃ of incubators effect 2 hours.It is centrifugal to take out the back, abandons supernatant, washes once with 1640, with culture medium to the 50 ten thousand cells/ml of 20% hyclone, with the ulinastatin adding culture plate of the infection cell for preparing and the variable concentrations of correspondence.Put 37 ℃, 5% CO
2In the incubator.Change liquid after 48 hours, continued to hatch 48 hours.Get basic supernatant and measure P24 antigen with the U.S. P24 of Organon Teknika company antigen test box.According to calculating virus concentration in each hole, calculate the suppression ratio of medicine to virus replication.
2.2 MTT cytotoxicity test
The MT4 cell is assigned to 500,000/ml with the culture medium that contains 20% hyclone, adds cell that 100 μ l prepare and the ulinastatin of 100 μ l and go into 96 well culture plates, 37 ℃, 5% CO
2Cultivated 6 days in the incubator; Take out every hole, back and absorb 150 μ l supernatants; Add MTT (0.25%) the 25 μ l that newly joins, 37 ℃ act on 4 hours down, in every hole, add 100 μ lDMSO and fully dissolve formed crystallization; With BIO-RAD company 550 type ELIASA readings (570nm), calculate cell survival rate.The base computational methods are: cell inhibitory rate=(cell control well OD value-dosing cell hole OD value) ÷ cell control well OD value * 100%.
3, result
3.1 anti-HIV-1 experimental result
| Ulinastatin concentration (μ g/ml) | The OD value | Virus quantity in the supernatant (pg) | Suppression ratio |
| 1000 | 0.832 | 57 | 52% |
| 800 | 0.305 | 22 | 84% |
| 500 | 0.021 | 3 | 97% |
| 400 | 0.011 | 0 | 100% |
| 200 | 0.015 | 1 | 99% |
| 100 | 0.399 | 25 | 78.3% |
| 50 | 0.996 | 64 | 44.4% |
| Virus control | 1.798 | 115.3 | ? |
| The cell contrast | 0.013 | ? | ? |
3.2 cytotoxicity result
| Ulinastatin concentration (μ g/ml) | The OD value | Pair cell toxicity rate |
| 1000 | 0.503 | 47.7% |
| 800 | 0.592 | 38.5% |
| 500 | 0.685 | 28.8% |
| 400 | 0.707 | 26% |
| 200 | 0.725 | 24% |
| 100 | 0.89 | 7.5% |
| 50 | 0.87 | 9.5% |
| The cell contrast | 0.962 | ? |
Find by above result, ulinastatin to HIV-1 virus actute infection inhibition test in, in the culture medium to 20% hyclone of 500,000 cells/ml of containing HIV-1; Ulinastatin pair cell toxicity rate is linear; But ulinastatin is not linear to the suppression ratio of HIV-1 virus, add ulinastatin 0.4mg/ml and can reach 100% suppression ratio, and along with the further increase of ulinastatin concentration; Suppression ratio to HIV-1 virus reduces, and pair cell toxicity rate continues to increase.Therefore, the ulinastatin of 0.2～0.4mg/ml concentration is best to the inhibition effect of HIV-1 virus, the interval that pair cell toxicity is the most moderate.
As stated, although represented and explained the present invention that with reference to specific preferred embodiment it shall not be construed as the restriction to the present invention self.Under the spirit and scope of the present invention prerequisite that does not break away from the accompanying claims definition, can make various variations in form with on the details to it.
Claims (6)
1. ulinastatin is as the application of preparation anti-HIV-1 virus drugs, and the concentration of ulinastatin is 200～400 μ g/ml.
2. application according to claim 1 is characterized in that: the concentration of said ulinastatin is 400 μ g/ml.
3. application according to claim 1 is characterized in that: the concentration of said ulinastatin is 200 μ g/ml.
4. application according to claim 1 is characterized in that: also comprise pharmaceutically acceptable auxiliaries in the said medicine.
5. application according to claim 4 is characterized in that: said medicine is a lyophilized injectable powder, and said pharmaceutically acceptable auxiliaries is any one or a few in mannitol, lactose, gelatin hydrolysate, sodium chloride or the glucose sugar.
6. application according to claim 4 is characterized in that: said medicine is an injection, and said pharmaceutically acceptable auxiliaries is any one or a few in water for injection, mannitol, sodium chloride or the glucose.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101231589A CN102614502A (en) | 2012-04-25 | 2012-04-25 | Application of ulinastatin to preparing anti-HIV (Human Immunodeficiency Virus)-1 virus medicament |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101231589A CN102614502A (en) | 2012-04-25 | 2012-04-25 | Application of ulinastatin to preparing anti-HIV (Human Immunodeficiency Virus)-1 virus medicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102614502A true CN102614502A (en) | 2012-08-01 |
Family
ID=46554948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012101231589A Pending CN102614502A (en) | 2012-04-25 | 2012-04-25 | Application of ulinastatin to preparing anti-HIV (Human Immunodeficiency Virus)-1 virus medicament |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102614502A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105797143A (en) * | 2016-05-30 | 2016-07-27 | 广东天普生化医药股份有限公司 | Application of ulinastatin containing composition to preparation of medicines for treating bladder cancers |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5504065A (en) * | 1988-11-28 | 1996-04-02 | Jcr Pharmaceuticals Co., Ltd. | Agent for treating or preventing AIDS using human urine trypsin inhibitor |
-
2012
- 2012-04-25 CN CN2012101231589A patent/CN102614502A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5504065A (en) * | 1988-11-28 | 1996-04-02 | Jcr Pharmaceuticals Co., Ltd. | Agent for treating or preventing AIDS using human urine trypsin inhibitor |
Non-Patent Citations (1)
| Title |
|---|
| 张苗等: "蛋白酶抑制剂的应用进展", 《农机化研究》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105797143A (en) * | 2016-05-30 | 2016-07-27 | 广东天普生化医药股份有限公司 | Application of ulinastatin containing composition to preparation of medicines for treating bladder cancers |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ito et al. | Inhibitory effect of glycyrrhizin on the in vitro infectivity and cytopathic activity of the human immunodeficiency virus [HIV (HTLV-III/LAV)] | |
| CN105693867B (en) | People sDR5-Fc recombination fusion protein and its new opplication | |
| CN114392256B (en) | Application of cyanidin in prevention and treatment of vascular calcification | |
| US20170128514A1 (en) | Pharmaceutical composition for treating cardio-cerebrovascular diseases and method for preparing the same | |
| Nyarko et al. | A comparison analysis on remdesivir, favipiravir, hydroxychloroquine, chloroquine and azithromycin in the treatment of corona virus disease 2019 (COVID-19)-A Review | |
| CN101019893A (en) | Process of enriching effective antitumor part of periplaneta americana with polyamide | |
| CN102614502A (en) | Application of ulinastatin to preparing anti-HIV (Human Immunodeficiency Virus)-1 virus medicament | |
| KR19990015612A (en) | Hepatitis C Therapeutic Composition Containing Mixed Extracts of Hwangbaekpi and Matari Plants | |
| CN102755335A (en) | Application of triptolide in preparation of medicament for treating or preventing human immunodeficiency viruses (HIV) | |
| AU711634B2 (en) | Compositions having antiviral properties and preparation process | |
| EP0255420B1 (en) | Antiviral agent for inhibiting growth of virus of acquired immune deficiency syndrome (aids) | |
| Mohan | Problems and perspectives in the design of anti‐HIV‐1 agents | |
| CN107007826B (en) | Active protein of isatis root and its preparing process and application | |
| JPH01149730A (en) | Retrovirus growth inhibitor | |
| Karadeniz et al. | Antiviral activities of marine algal extracts | |
| Yuson-Sunga et al. | The The Effect of Carica papaya Leaf Extract on Increasing Platelet Count among Dengue Fever Patients: A Meta-Analysis | |
| KR20200026156A (en) | Pharmatheutical composition comprising Tenofovir disoproxil fumarate for preventing or treating of hepatic fibrosis | |
| CN112656938B (en) | Application of ginsenoside Re and lysozyme in preparation of medicine for treating or preventing abdominal aortic aneurysm | |
| Islam et al. | An in‐depth analysis of COVID‐19 treatment: Present situation and prospects | |
| CN115957222B (en) | Application of Efavirennz in preparation of anti-adenovirus ADV7 drug | |
| CN108823162A (en) | Recombinant human lysozyme is preparing the application in anti-AIDS drug | |
| CN109481487A (en) | Application of the taraxasterone in the drug of preparation prevention and treatment senile dementia | |
| Kumari et al. | ACE2: A double-edged sword against SARS cov-2 associated cardiovascular complications and endothelial dysfunction | |
| CN101011567A (en) | Medicament for treating AIDS and its preparing method | |
| CN101836973A (en) | New application of amide compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120801 |